Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SWOG S1605
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
- NCT02844816 ↗
- Completed
- National Cancer Institute (NCI)
- Standard
We haven't built an HCP commentary report on SWOG S1605 (atezolizumab in BCG-unresponsive high-risk non-muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWOG S1605 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Recurrent Bladder Urothelial Carcinoma; Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7; Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7; Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
- Interventions
- Atezolizumab
- Arms
- Treatment (atezolizumab) · Experimental
- Enrollment
- 172
- Primary outcomes
- Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS)
- Event-free Survival (EFS)
- Sponsor
- National Cancer Institute (NCI) with Canadian Cancer Trials Group
- Start
- Mar 13, 2017
- Primary completion
- Jun 1, 2023
- Results posted
- Yes
- Registry record
- NCT02844816 · updated May 22, 2025
Publications
linked from the registry- Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM Jr, Lerner SP. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 Dec;84(6):536-544. doi: 10.1016/j.eururo.2023.08.004. Epub 2023 Aug 16. PubMed 37596191